Table 5 The GEE model for LLV events (defined as 50–999 copies/ml) of developing VF events (defined as ≥ 1000 copies/ml)

Male (vs. Female)

0.318 (0.091, 1.106)

‒68.2 (‒90.9, 10.6)

0.072

Age > 25 (vs. < 25 years)

2.391 (0.877, 6.519)

139.1 (‒12.3, 551.9)

0.088

Homosexual Transmission (vs. other)

2.164 (0.685, 6.834)

116.4 (‒31.5, 583.4)

0.188

Time from diagnosis to treatment ≤ 1 (vs. > 1 months)

1.273 (0.5, 3.243)

27.3 (‒50, 224.3)

0.612

CD4 + T cell count at baseline ≤ 200 (vs. > 200 cells/µL)

1.448 (0.463, 4.526)

44.8 (‒53.7, 352.6)

0.525

Viral load at baseline > 100,000 (vs. ≤ 100,000 copies/mL

1.101 (0.282, 4.296)

10.1 (‒71.8, 329.6)

0.890

LLV events during follow-up. (Yes vs. No) ^a

3.215 (1.097, 9.421)

221.5 (9.7, 842.1)

0.033

INSTIs-based regimen (vs. PIs-based regimen)

0.221 (0.084, 0.584)

‒77.9 (‒91.6, ‒41.6)

0.002